
|Videos|August 9, 2022
Factors for Consideration when Choosing an ADT Regimen for mCSPC
Author(s)Jason Hafron, MD
Jason Hafron, MD, revisits the patient profile and discusses factors that inform treatment decision-making in mCSPC.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
BOND-003 Cohort C: Efficacy Results
4
Individualizing androgen pathway therapy in mCSPC
5









